AIM ImmunoTech
13 hedge funds and large institutions have $248K invested in AIM ImmunoTech in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
0% more funds holding
Funds holding: 13 → 13 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
55% less capital invested
Capital invested by funds: $557K → $248K (-$309K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$10.1K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$8.26K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$7.34K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$6.42K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.67K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$263K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
-$9K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.34K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
BlackRock
New York
| $84K | +$918 | +1 | +1% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $80K | -$7.34K | -8 | -7% |
|
|
3
Citadel Advisors
Miami,
Florida
| $26K | +$7.34K | +8 | +33% |
|
4
Geode Capital Management
Boston,
Massachusetts
| $13K | – | – | – |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $11K | +$8.26K | +9 | +180% |
|
|
6
UBS Group
Zurich,
Switzerland
| $9K | +$3.67K | +4 | +50% |
|
|
PP
7
Paloma Partners
Greenwich,
Connecticut
| $9K | +$10.1K | +11 | New |
|
8
Northern Trust
Chicago,
Illinois
| $5K | – | – | – |
|
|
TSS
9
Two Sigma Securities
New York
| $5K | +$6.42K | +7 | New |
|
|
OAM
10
Occidental Asset Management
Burlingame,
California
| $3K | – | – | – |
|
11
Invesco
Atlanta,
Georgia
| $2K | – | – | – |
|
|
WPW
12
Waldron Private Wealth
Bridgeville,
Pennsylvania
| $1K | – | – | – |
|
|
SM
13
Sabby Management
Miami Beach,
Florida
| – | -$263K | -260 | Closed |
|
|
14
Creative Planning
Overland Park,
Kansas
| – | -$9K | -9 | Closed |
|
AIM Hedge Fund Activity: Q4 2018 in Review
13 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q4 2018, worth a combined $248K — down 55% from $557K a quarter earlier.
Fund positioning in AIM was balanced in Q4 2018: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 1 trimmed.
The largest buyer was Paloma Partners, opening a new position worth an estimated $10.1K. The largest seller was Sabby Management, exiting entirely with an estimated $263K sold.
- 13 institutional investors held AIM ImmunoTech (AIM) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $248K of AIM ImmunoTech stock for Q4 2018, down 55% quarter-over-quarter.
- 2 funds opened new AIM ImmunoTech positions in Q4 2018 and 2 closed out, a net change of 0 holders.
- The largest AIM ImmunoTech buyer in Q4 2018 was Paloma Partners, an estimated $10.1K added.
- The largest AIM ImmunoTech seller in Q4 2018 was Sabby Management, an estimated $263K sold.
Based on aggregated 13F filings for Q4 2018.